Lisata Therapeutics, Inc. (LSTA)

Lisata Therapeutics has experienced several significant stock events in the past six months. The company entered into a binding term sheet to be acquired by Kuva Labs, Inc., followed by a definitive agreement with revised terms. Lisata Therapeutics mutually terminated its license agreement with Qilu Pharmaceutical, regaining rights for certepetide in the Greater China region. The company reported its Q3 2025 financial results, highlighting cash and investments, operating expenses, and positive data from clinical studies. Positive preclinical results with Catalent were presented, showing improved tumor-selective penetration and enhanced ADC efficacy, and Lisata and Catalent entered into a nonexclusive license agreement for the use of certepetide. A strategic alliance was formed with GATC Health to utilize their AI-powered Multiomics Advanced Technology™ drug discovery platform. LSTA's share price has been volatile, with a significant increase compared to the previous year.

Information regarding the direct demand seasonality for Lisata Therapeutics' products and services is not explicitly available, as the company is clinical-stage and its lead product, certepetide, is still under development and not yet commercialized. Therefore, there is no current market demand seasonality for its products. However, historical data related to LSTA stock performance suggests some seasonality in investor behavior, with November showing the highest probability of a positive return and October the lowest.

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases. The company operates in the healthcare sector, specifically in the biotechnology industry, focusing on biopharmaceuticals and drug discovery. Its lead product candidate is certepetide, designed to enhance the delivery of anti-cancer drugs directly to tumors. Certepetide is currently in Phase 2 clinical studies for various solid tumors and has received Orphan Drug and Fast Track status from the FDA for pancreatic cancer, as well as Orphan Drug Designation for glioma, osteosarcoma, and cholangiocarcinoma, and Rare Pediatric Disease Designation for osteosarcoma in the U.S. In addition to certepetide, Lisata Therapeutics also has clinical development programs based on its autologous CD34+ cell therapy technology platform.

Lisata Therapeutics, Inc. is headquartered in Basking Ridge, New Jersey, United States. The company's operations and clinical trials for certepetide have an international scope, involving global partnerships and clinical studies. For instance, Qilu Pharmaceutical, a former licensee, was developing certepetide in the Greater China region. The company also collaborates with academic institutions and contract research organizations, supporting clinical studies and translational research efforts in North America and Europe.

Lisata Therapeutics has received positive recognition for its work in the past year. The company won the BioTech Breakthrough Award for 'Overall BioPharma Solution of the Year' for the second consecutive year, highlighting its CendR Platform® technology for enhancing tumor-targeted drug delivery. No specific negative events significantly impacting the company's brand reputation in the past year were found in the search results.

Lisata Therapeutics, Inc. has a mixed ownership structure, including institutional, insider, and retail investors. As of early April 2026, Lisata Therapeutics had 26 institutional owners and shareholders holding a total of 729,051 shares. Insiders hold a significant portion of the company's stock. Rimasia Capital Partners Manager Ltd is noted as the largest individual shareholder. David Mazzo, the CEO, also owns a substantial number of shares.